Notification
No new Notification messages
Zinka Logistics Solutions IPO is Open!
Apply for the Zinka Logistics Solutions IPO through UPI in just minutes.
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
beta drugs limited stock

BETA DRUGS LIMITED Share Price

1990 -25.00 (-1.24%)
Nov 21 2024 03:26 PM Pharmaceuticals NSE: BETA

BETA DRUGS LIMITED Share Price Update

As of the latest trading session, BETA DRUGS LIMITED share price is currently at 1990, which is down by -25.00 from its previous closing. Today, the stock has fluctuated between 1931.25 and 2026.90. Over the past year, BETA DRUGS LIMITED has achieved a return of 67.91 %. In the last month alone, the return has been 11.50 %. Read More...

BETA DRUGS LIMITED Performance

Day Range

Low1931.25 High2026.90
1983.00

52 Week Range

Low 1060.05 High 2326.00
1983.00

BETA DRUGS LIMITED Share Price

81

BETA

img img img img
No Data Available

Open Price

2016.00

Prev. Close

2015.00

Volume (Shares)

4000.00

Total traded value

79.32

Upper Circuit

2418.00

Lower Circuit

1612.00

Note: The current prices & values are delayed, Login to your account for live updates.

BETA DRUGS LIMITED Fundamentals


(Standalone)

Market Cap (Cr) 1913.14
PE Ratio (TTM) 86.90
Book Value / Share 120.67
Beta 0.74
ROE 20.67%
EPS (TTM) 22.82
Dividend Yield 0.00%
Net Profit Qtr (Cr) 0.00

BETA DRUGS LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars MAR 2024 (Values in Cr)
Revenue 197.62
Operating Expense 169.87
Net Profit 21.94
Net Profit Margin (%) 11.10
Earnings Per Share (EPS) 22.82
EBITDA 35.25
Effective Tax Rate (%) 25.61
Particulars MAR 2023 (Values in Cr)
Revenue 157.87
Operating Expense 133.71
Net Profit 18.82
Net Profit Margin (%) 11.92
Earnings Per Share (EPS) 19.57
EBITDA 32.24
Effective Tax Rate (%) 25.34
Particulars MAR 2022 (Values in Cr)
Revenue 124.85
Operating Expense 105.53
Net Profit 14.25
Net Profit Margin (%) 11.41
Earnings Per Share (EPS) 14.82
EBITDA 26.04
Effective Tax Rate (%) 29.36
Particulars MAR 2021 (Values in Cr)
Revenue 79.46
Operating Expense 70.17
Net Profit 6.98
Net Profit Margin (%) 8.78
Earnings Per Share (EPS) 7.26
EBITDA 15.92
Effective Tax Rate (%) 29.35
Particulars MAR 2020 (Values in Cr)
Revenue 65.32
Operating Expense 56.79
Net Profit 7.10
Net Profit Margin (%) 10.86
Earnings Per Share (EPS) 7.49
EBITDA 12.17
Effective Tax Rate (%) 20.67
Particulars MAR 2024 (Values in Cr)
Book Value / Share 163.43
ROE % 26.03
ROCE % 31.58
Total Debt to Total Equity 0.12
EBITDA Margin 20.75
Particulars MAR 2023 (Values in Cr)
Book Value / Share 127.82
ROE % 28.55
ROCE % 32.63
Total Debt to Total Equity 0.19
EBITDA Margin 23.72
Particulars MAR 2022 (Values in Cr)
Book Value / Share 96.05
ROE % 30.85
ROCE % 34.77
Total Debt to Total Equity 0.24
EBITDA Margin 23.64
Particulars MAR 2021 (Values in Cr)
Book Value / Share 71.37
ROE % 18.64
ROCE % 21.20
Total Debt to Total Equity 0.32
EBITDA Margin 21.74
Particulars MAR 2020 (Values in Cr)
Book Value / Share 59.41
ROE % 19.22
ROCE % 19.97
Total Debt to Total Equity 0.43
EBITDA Margin 20.17
Particulars MAR 2024 (Values in Cr)
Book Value / Share 120.67
ROE % 20.67
ROCE % 26.60
Total Debt to Total Equity 0.05
EBITDA Margin 17.84
Particulars MAR 2023 (Values in Cr)
Book Value / Share 100.12
ROE % 21.67
ROCE % 27.20
Total Debt to Total Equity 0.07
EBITDA Margin 20.42
Particulars MAR 2022 (Values in Cr)
Book Value / Share 80.57
ROE % 20.23
ROCE % 26.19
Total Debt to Total Equity 0.09
EBITDA Margin 20.86
Particulars MAR 2021 (Values in Cr)
Book Value / Share 65.96
ROE % 11.65
ROCE % 15.59
Total Debt to Total Equity 0.12
EBITDA Margin 20.04
Particulars MAR 2020 (Values in Cr)
Book Value / Share 58.71
ROE % 14.63
ROCE % 16.64
Total Debt to Total Equity 0.17
EBITDA Margin 18.63
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 28.63
Total Assets 254.09
Total Liabilities 254.09
Total Equity 157.11
Share Outstanding 9613790
Price to Book Ratio 10.22
Return on Assets (%) 14.33
Return on Capital (%) 21.67
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 19.16
Total Assets 198.42
Total Liabilities 198.42
Total Equity 122.88
Share Outstanding 9613790
Price to Book Ratio 6.26
Return on Assets (%) 15.48
Return on Capital (%) 22.11
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 17.32
Total Assets 157.85
Total Liabilities 157.85
Total Equity 92.34
Share Outstanding 9613790
Price to Book Ratio 7.02
Return on Assets (%) 15.72
Return on Capital (%) 22.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 10.42
Total Assets 117.50
Total Liabilities 117.50
Total Equity 68.61
Share Outstanding 9613790
Price to Book Ratio 1.82
Return on Assets (%) 9.97
Return on Capital (%) 14.08
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 5.38
Total Assets 107.17
Total Liabilities 107.17
Total Equity 57.11
Share Outstanding 9613790
Price to Book Ratio 0.68
Return on Assets (%) 8.78
Return on Capital (%) 12.22
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 27.19
Total Assets 170.47
Total Liabilities 170.47
Total Equity 116.01
Share Outstanding 9613790
Price to Book Ratio 10.22
Return on Assets (%) 12.86
Return on Capital (%) 18.34
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 17.79
Total Assets 134.04
Total Liabilities 134.04
Total Equity 96.25
Share Outstanding 9613790
Price to Book Ratio 6.26
Return on Assets (%) 14.03
Return on Capital (%) 18.82
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 15.58
Total Assets 110.89
Total Liabilities 110.89
Total Equity 77.46
Share Outstanding 9613790
Price to Book Ratio 7.02
Return on Assets (%) 12.84
Return on Capital (%) 17.24
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 8.26
Total Assets 86.23
Total Liabilities 86.23
Total Equity 63.41
Share Outstanding 9613790
Price to Book Ratio 1.82
Return on Assets (%) 8.09
Return on Capital (%) 10.37
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 4.16
Total Assets 82.21
Total Liabilities 82.21
Total Equity 56.43
Share Outstanding 9613790
Price to Book Ratio 0.68
Return on Assets (%) 8.63
Return on Capital (%) 11.12
Particulars MAR 2024 (Values in Cr)
Net Income 48.75
Cash from Operations 30.93
Cash from Investing -13.97
Cash from Financing -7.48
Net change in Cash 9.46
Free Cash Flow 42.54
Particulars MAR 2023 (Values in Cr)
Net Income 41.05
Cash from Operations 23.38
Cash from Investing -19.06
Cash from Financing -2.47
Net change in Cash 1.83
Free Cash Flow 41.59
Particulars MAR 2022 (Values in Cr)
Net Income 34.30
Cash from Operations 29.62
Cash from Investing -21.75
Cash from Financing -0.97
Net change in Cash 6.89
Free Cash Flow 49.05
Particulars MAR 2021 (Values in Cr)
Net Income 15.95
Cash from Operations 18.59
Cash from Investing -5.84
Cash from Financing -7.71
Net change in Cash 5.03
Free Cash Flow 24.35
Particulars MAR 2020 (Values in Cr)
Net Income 11.97
Cash from Operations 8.41
Cash from Investing -15.05
Cash from Financing 8.72
Net change in Cash 2.08
Free Cash Flow 23.71
Particulars MAR 2024 (Values in Cr)
Net Income 29.48
Cash from Operations 21.18
Cash from Investing -11.02
Cash from Financing -0.76
Net change in Cash 9.40
Free Cash Flow 27.62
Particulars MAR 2023 (Values in Cr)
Net Income 25.20
Cash from Operations 10.22
Cash from Investing -5.81
Cash from Financing -2.19
Net change in Cash 2.21
Free Cash Flow 17.13
Particulars MAR 2022 (Values in Cr)
Net Income 20.16
Cash from Operations 18.76
Cash from Investing -12.71
Cash from Financing 1.26
Net change in Cash 7.31
Free Cash Flow 28.37
Particulars MAR 2021 (Values in Cr)
Net Income 9.88
Cash from Operations 11.59
Cash from Investing -3.15
Cash from Financing -4.34
Net change in Cash 4.10
Free Cash Flow 15.03
Particulars MAR 2020 (Values in Cr)
Net Income 8.95
Cash from Operations 6.09
Cash from Investing -14.32
Cash from Financing 9.47
Net change in Cash 1.24
Free Cash Flow 13.60
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 55.85 32.10 3.04 428.00 37.54 / 77.70
BLISS GVS PHARMA LTD 120.75 15.11 1.25 1271.52 92.25 / 148.95
CIPLA LTD 1471.35 25.74 4.18 118825.56 1165.10 / 1702.00
FERMENTA BIOTECH LIMITED 331.20 115.00 3.35 974.75 145.00 / 354.60
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 55.85 48.57 9.49 428.00 37.54 / 77.70
AMRUTAJAN HEALTH LTD 720.90 43.85 6.99 2084.17 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6497.50 126.19 23.91 16243.75 4050.15 / 8139.85
BLISS GVS PHARMA LTD 120.75 15.72 1.24 1271.52 92.25 / 148.95

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 2042.80
  • 26 Days 1951.50
  • 10 Days 2040.90
  • 50 Days 1879.80
  • 12 Days 2030.30
  • 100 Days 1667.10
  • 20 Days 1978.70
  • 200 Days 1452.30
2006.78
PIVOT
First Resistance 2033.02
Second Resistance 2063.23
Third Resistance 2089.47
First Support 1976.57
Second Support 1950.33
Third Support 1920.12
RSI 55.48
MACD 78.73
Commodity Channel Index (CCI) 33.30
ADX 35.35
Williams % R -67.03

Over 1 Month

down

11.50

Over 3 Months

down

44.82

Over 6 Months

down

60.81

Over 1 Year

down

67.91

Over 3 Years

down

61.99

Over 5 Years

down

89.02

BETA DRUGS LIMITED Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

BETA DRUGS LIMITED Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
32.1
Promoter Holdings
66.73
FII
1.15
DII
0.0
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Neeraj Batra Shareholding of Promoter and Promoter Group 6341663.0 65.96
Ashish Kacholia Public Shareholding 556000.0 5.78
Onkar Singh Public Shareholding 100800.0 1.05
Rahul Batra Shareholding of Promoter and Promoter Group 39650.0 0.41
Varun Batra Shareholding of Promoter and Promoter Group 33230.0 0.35
Heena Batra Shareholding of Promoter and Promoter Group 590.0 0.01
Aditi Batra Shareholding of Promoter and Promoter Group 590.0 0.01

BETA DRUGS LIMITED

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
Ex-Date Ex-Bonus Ratio
Ex-Date Old FV NEW FV Record Date

Learn More About Stocks

About BETA DRUGS LIMITED

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by BETA DRUGS LIMITED

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Beta Drugs Ltd?

Answer Field

The share price of Beta Drugs Ltd for NSE is ₹ 1990 and for BSE is ₹ 0.00.

What is the Market Cap of Beta Drugs Ltd?

Answer Field

The market cap of Beta Drugs Ltd for NSE is ₹ 19,13.14 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Beta Drugs Ltd?

Answer Field

The 52 Week High and Low of Beta Drugs Ltd for NSE is ₹ 2326.00 and ₹ 1060.05 and for BSE is ₹ 0.00 and ₹ 0.00.

How to Buy Beta Drugs Ltd share?

Answer Field

You can trade in Beta Drugs Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Beta Drugs Ltd?

Answer Field

The 1 year returns on the stock has been 67.91%.

What is the Current Share Price of Beta Drugs Ltd?

Answer Field

Beta Drugs Ltd share price is for NSE ₹ 1990 & for BSE ₹ 0.00 as on Nov 21 2024 03:26 PM.

What is the Market Cap of Beta Drugs Ltd Share?

Answer Field

The market cap of Beta Drugs Ltd for NSE ₹ 19,13.14 & for BSE ₹ 0.0 as on Nov 21 2024 03:26 PM.

What is the P/E Ratio of Beta Drugs Ltd Share?

Answer Field

As on Nov 21 2024 03:26 PM the price-to-earnings (PE) ratio for Beta Drugs Ltd share is 86.90.

What is the PB ratio of Beta Drugs Ltd Share?

Answer Field

As on Nov 21 2024 03:26 PM, the price-to-book (PB) ratio for Beta Drugs Ltd share is 120.67.

How to Buy Beta Drugs Ltd Share?

Answer Field

You can trade in Beta Drugs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Beta Drugs Ltd Share on Bajaj Broking App?

Answer Field

To buy Beta Drugs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Beta Drugs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text
loader